Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
出版年份 2013 全文链接
标题
Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
作者
关键词
Insulin Glargine, Sitagliptin, Basal Insulin, Insulin Aspart, Insulin Detemir
出版物
DRUGS
Volume 73, Issue 6, Pages 575-593
出版商
Springer Nature
发表日期
2013-05-01
DOI
10.1007/s40265-013-0051-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES CARE
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
- (2013) Chantal Mathieu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec
- (2012) Dorte B. Steensgaard et al. BIOCHEMISTRY
- Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial
- (2012) I. B. Hirsch et al. DIABETES CARE
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
- (2012) B. Zinman et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2013
- (2012) DIABETES CARE
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
- (2012) R. E. Ratner et al. DIABETES OBESITY & METABOLISM
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials
- (2012) N. Freemantle et al. DIABETIC MEDICINE
- Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec
- (2012) Jennifer D. Robinson et al. DRUGS
- Insulin Detemir
- (2012) Gillian M. Keating DRUGS
- Insulin degludec: a new ultra-longacting insulin
- (2012) Abd A Tahrani et al. LANCET
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Alan J Garber et al. LANCET
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Simon Heller et al. LANCET
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Efficacy and safety of ultra-long-acting insulin degludec
- (2012) Ammar Wakil et al. Therapeutic Advances in Endocrinology and Metabolism
- Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
- (2012) Fei Wang et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naive People With Type 2 Diabetes: A randomized, controlled trial
- (2011) T. Heise et al. DIABETES CARE
- Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
- (2011) K. I. Birkeland et al. DIABETES CARE
- A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
- (2011) M. Evans et al. DIABETES OBESITY & METABOLISM
- Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
- (2011) Bernard Zinman et al. LANCET
- Diabetes and Cancer: A consensus report
- (2010) E. Giovannucci et al. DIABETES CARE
- How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
- (2010) S. Arnolds et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The role of alpha-gustducin, in the effect of T2R-agonists on the secretion and physiological effects of ghrelin
- (2010) Sara Janssen et al. REGULATORY PEPTIDES
- No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis
- (2009) A. Dejgaard et al. DIABETOLOGIA
- Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
- (2008) J. S. Skyler et al. DIABETES CARE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now